Despite not being utilized as considerably as other antidepressants in the therapy of
depression, the monoamine oxidase inhibitors (MAOIs) proceed to hold a place in …

Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the
oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine …

Colorimetric and fluorescent probes based on small organic molecules have become
important tools in modern biology because they provide dynamic information concerning the …

Background: Monoamine oxidases (MAOs) were discovered nearly a century ago. This
article aims to analyze the research literature landscape associated with MAOs as privileged …

In the last years the continuous efforts in the development of novel and effective inhibitors of
human monoamine oxidases (hMAOs) promoted the discovery of new agents able to …

Monoamine oxidase enzyme is necessary for the management of brain functions. It
oxidatively metabolizes monoamines and produces ammonia, aldehyde and hydrogen …

Monoamine oxidase is a flavin enzyme that catalyzes the oxidation of monoamine
neurotransmitters in the brain. Various toxic by-products, aldehydes and hydrogen peroxide …

Alzheimer's disease (AD), a multifactorial complex neural disorder, is categorized with
progressive memory loss and cognitive impairment as main clinical features. The multitarget …

Alzheimer's disease (AD) is the most common form of dementia among the elderly,
accounting for 60% to 70% of cases. At present, the pathogenesis of this condition remains …

Depression is the single largest contributor to global disability with a huge economic and
social burden on the world. There are a number of antidepressant drugs on the market, but …